Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 16, 2011

View Archived Issues

Novel protein kinase inhibitors reported

PANORAMA 1 study evaluates panobinostat in multiple myeloma

Phase III trial assesses olesoxime plus riluzole in ALS

PARP inhibitor shows promise combined with temozolomide in advanced solid tumors

GeoVax Labs vaccinates first patient in phase I/II AIDS trial

Liquidia Technologies and PATH to collaborate

Catalyst Pharmaceutical moves CPP-115 into clinic

NKTR-181 trial yields promising results

BioLineRx to develop novel peptide drugs discovered by Compugen

Camurus grants Novartis exclusive licensing options

Threshold reports encouraging results from ongoing TH-302 trial in advanced leukemias

GSK files for Japanese approval of oral kinase inhibitor in malignant soft tissue sarcoma

New schistosomiasis vaccine candidate developed in Switzerland

New malaria vaccines tested in vivo by U.S. investigators

AVL-292 may alleviate myeloma-related bone disease

Phase II data encourage further development of aminopeptidase N inhibitor in leukemia

Salix Pharmaceuticals files NDA for crofelemer

Metabolic Pharmaceuticals begins investigating AOD-9604 in two new areas

Onyx Pharmaceuticals joins MMRF's personalized medicine initiative

New conjugated antisense oligonucleotides prepared in U.S.

Novel histamine H3 receptor antagonists/inverse agonists disclosed

Chinese institute patents novel serotonin modulators

Kyowa Hakko Kirin presents novel kynurenine production inhibitors

Wilex discusses development of Redectane with FDA

Catabasis raises additional funding for CAT-2003 development in hypertriglyceridemia

Dako's HER2 CISH pharmDx kit approved in U.S.

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...